logo

For the Inventor, By the Inventor

Eugene, OR, United States of America

Shervin Esfandiari

This inventor holds 11 USPTO granted patents and 1 published patent application. Top assignee: Allergan, Inc.. Active years: 1997-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shervin Esfandiari. Retrieved from https://idiyas.com/inventor/shervin-esfandiari

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 90.9

Average Co-Inventor Count = 4.5

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:

goldMedal11 out of 2,287 
 
Allergan, Inc.
 patents

Years Active: 1997-2017

Loading Chart...
11 patents (USPTO):Explore Patents
1. 9540332 - Benzimidazole derivatives as selective blockers of persistent sodium current (2017-01-10),
2. 8859780 - Benzimidazole derivatives as selective blockers of persistent sodium current (2014-10-14),
3. 7919630 - [object Object] (2011-04-05),
4. 7880017 - Process for the synthesis of imidazoles (2011-02-01),
5. 7598394 - Process for the synthesis of imidazoles (2009-10-06),
6. 7579481 - Method of making imidazole-2-ones and 2-thiones (2009-08-25),
7. 7294716 - Process for preparing isomerically pure prodrugs of proton pump inhibitors (2007-11-13),
8. 7183305 - Process for the synthesis of imidazoles (2007-02-27),
9. 7115748 - Method of making imidazole-2-thiones (2006-10-03),
10. 5675038 - Lithium and amine dissolving metal reduction (1997-10-07),
11. 5675019 - Process for making piloloctam and derivatives thereof (1997-10-07),

Title: Shervin Esfandiari: Innovator in Pharmaceutical Chemistry

Introduction

Shervin Esfandiari is a prominent inventor based in Eugene, OR (US). He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 11 patents. His work focuses on developing innovative compounds that address various medical conditions.

Latest Patents

One of his latest patents involves benzimidazole derivatives as selective blockers of persistent sodium current. This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof. The patent outlines pharmaceutical compositions comprising this compound and methods for treating diseases or conditions mediated by elevated persistent sodium current, such as ocular disorders, multiple sclerosis, seizure disorders, and chronic pain.

Career Highlights

Shervin Esfandiari is currently associated with Allergan, Inc., where he continues to advance his research and development efforts. His work has been instrumental in creating effective treatments that improve patient outcomes.

Collaborations

He has collaborated with notable colleagues, including Lloyd Jay Dolby and Michael E Garst, contributing to a dynamic research environment that fosters innovation.

Conclusion

Shervin Esfandiari's contributions to pharmaceutical chemistry and his innovative patents highlight his commitment to improving healthcare solutions. His work continues to impact the medical field positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…